(UroToday.com) At the ESMO 2020 virtual annual meeting, Dr. Eleni Efstathiou reviewed several key studies presented during the prostate cancer session. Dr. Efstathiou notes that over the last several decades we have been trying to offer treatment personalization based on the “therapeutic index”: efficacy / adverse events. There are several variables that need to be taken into consideration when discussing the personalization of treatment, including: